Sanofi (SNY) is making strategic moves to enhance its position in the pharmaceutical market. In collaboration with AstraZeneca, the company is preparing for the early Q3 shipment of Beyfortus, its infant RSV protection therapy. This initiative is aimed at ensuring the treatment's widespread availability by the 2025-2026 RSV season. The companies have significantly ramped up their production capabilities to cater to the rising demand for this important therapy.
https://www.gurufocus.com/news/2914548/sanofi-sny-expands-beyfortus-production-ahead-of-rsv-season
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.